WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Sweden beats France, Britain relegated after losing to Norway at hockey worlds
Maryland bus crash: 1 person killed and 23 injured
Tragedy as girl, 10, is killed in house fire that her mother and siblings
UK's ruling Conservative Party suffers heavy losses in local elections
Britain's new bonkers EV: Callum Skye is an £80k electric buggy built in Warwickshire
Cast of the Lord of the Rings pay tribute to late co
Fight to own Britain's biggest mega
Cast of the Lord of the Rings pay tribute to late co
Emily Blunt reveals kissing some of her Hollywood co
Investigators return to Long Island home of Gilgo Beach serial killing suspect
Taylor Pendrith gets 1st PGA Tour win at Byron Nelson after final